Cannara Biotech – www.shopCBD.com
Cannara Biotech (CSE:LOVE)(FRA:8CB)
Headquartered in Montreal, Cannara Biotech is entering the U.S. THC-CBD market, through a subsidiary, with an on-line e-commerce platform called shopCBD.
“We are taking a leadership role by creating a hub for vendors to showcase their products and consumers to purchase hemp-CBD products in a fast and easy way. We want to become the Amazon of CBD,” – ZOHAR KRIVOROT – CEO and Founder
Highlights
- Zohar Krivorot, president and chief executive officer of Cannara Biotech is a 15-year veteran in the tech and on-line industries.
- Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec and one of the largest in Canada
- shopcbd.com is a platform that will showcase hemp-CBD retail products including tinctures, oils, capsules, body care, vape cartridges and pet-related CBD infused treats
- The indoor facility offers lower risk of airborne infections, mold/mildew and produces a higher grade of cannabis
- The new e-commerce platform will showcase retail products from hemp-CBD manufacturers for the U.S. consumer market
- shopCBD will provide a user-friendly on-line experience where consumers can purchase, review and compare a variety of CBD products
Trending
- With the recent passing of the 2018 Farm Bill in the U.S., CBD represents an emerging sector with many vendors seeking national reach to U.S. customers.
- The company’s strategy is to offer a wide variety of products from leading CBD brands, with competitive pricing and delivery times across the U.S.
- The rise in popularity for CBD products is driven by consumers seeking natural-based health and wellness solutions to treat various ailments from inflammation, anxiety to insomnia amongst many others.
- The hemp-derived CBD market is expected to reach $22-billion (U.S.) by 2022 according to industry analysts at Brightfield Group.
Alongside the e-commerce, on-line platform, Cannara Biotech will have on-site independent THC and CBD brands, following the adoption of regulations on cannabis-infused edibles and beverages, that will produce and ship from the facility. Cannara Biotech’s facility will be a multi-purpose facility that will cultivate recreational cannabis and produce cannabinoid-infused products including edibles, cosmetics, pet products and beverages. These products will be shipped to stores and retail outlets in Canada and to international markets.
Cannara Biotech went public in Q1 of this year and is being traded on the CSE under the ticker “LOVE” and on the FRA under the ticker “8CB”. As of February 12th, 2019, LOVE closed at .22.
—
Isabelle Arsenault
Media Relations
MomentumPR
- Published in Cannara, Marijuana, Medical Marijuana
Cannara Biotech – Quebec’s largest cultivation facility
Cannara Biotech (CSE:LOVE)(FRA:8CB)
Headquartered in Montreal, Cannara Biotech is building the largest indoor cannabis cultivation facility in Quebec and one of the largest in Canada, a modern and secure 625,000-square-foot facility in Farnham, Quebec.
“Being in Quebec allows us to take advantage of the low cost of electricity and gives us a cost advantage over our competitors.” – ZOHAR KRIVOROT – CEO and Founder
Highlights
- Some 100,000 kg of cannabis production is expected per year once all 3 phases are operational. Today, phase 1 is being built with completion expected end of Q2 2019. Once completed, yield is expected at 15,000 kg.
- Cannara Biotech has raised $55M to date, has acquired 19 provisional patents for product exclusivity, and has developed 8 assorted THC/CBD infused product brands to add to their offerings.
- Low electricity cost in Quebec as well as reduced labour cost compared to the rest of Canada gives the Company a cost advantage over their competitors.
- Independent THC and CBD brands will be produced on-site accelerating speed to market.
- The Company will leverage the facility with joint-ventures to produce edibles, pet-products, cosmetics and beverages once the processing license is secured which is estimated for the end of 2019.
- The advantage of growing in an indoor facility offers lower risk of airborne infections, mold/mildew and produces a higher grade of cannabis.
- Cannara Biotech is building an online e-commerce platform (shopCbd.com) that will serve as a podium and distribution channel for US-CBD brands for the American market.
Closer look
Phase 1 will provide 130,000ft2 of growing space. Growing is expected to commence in the fall of 2019 with an estimated yield of 15,000kg.
Cannara Biotech raised $55 million from private investors during the introduction of this project and still have over $40 million in the bank with Phase 1 fully funded.
Phase 2 forecasted to be running by 2020 is 205,000ft2 and likely to yield 38,000kg per year. Phase 3 aiming to be operational in 2022 is 277,000ft2 and expected to produce 55,000kg per year. Cannara Biotech is looking to produce over 100,000kg per year once fully operational.
Currently, 300 sq. ft. space for Phase 2 is being rented by occupants that contribute to a rental revenue of $2 million per year. These earnings pay the monthly fee for the whole facility.
Cannara Biotech’s strategy is also to maximize on the low electricity rates Quebec has with its Hydro and low labour rates in Quebec.
Growing indoor cannabis often results in a higher grade of cannabis. Growing in a controlled environment, protected from many outdoor ailments and mildew creates a more consistent and desirable product for buyers and consumers.
Alongside selling cannabis to intermediaries who will transform the crop into their desired product, Cannara Biotech will have on-site independent THC and CBD brands, following the adoption of regulations on cannabis-infused edibles and beverages, that will produce and ship from the facility. Cannara Biotech’s facility will be a multi-purpose facility that will cultivate recreational cannabis and produce cannabinoid-infused products including edibles, cosmetics, pet products and beverages. These products will be shipped to stores and retail outlets in Canada and to international markets.
Cannara Biotech went public in Q1 of this year and is being traded on the CSE under the ticker “LOVE” and on the FRA under the ticker “8CB”. As of February 12th, 2019, LOVE closed at .22.
—
Isabelle Arsenault
Media Relations
MomentumPR
GROWPACKER – the next Amazon of cannabis?
GROWPACKER; THE NEXT AMAZON OF CANNABIS?
What could Amazon possibly offer to make them even more successful? Imagine they offered the manufacturing, branding, packaging and total distribution of every one of their client’s products.
Well that’s what California based GrowPacker does; except they do it for anything and everything related to the cannabis industry. With regards to everything I mean; non-alcoholic beverages, carbonated and non-carbonated beverages, water, candies, chocolate bars, brownies, cookies, creams, lotions, massage oils, vape oils, pre-rolls, flower and the list goes on…
Growpacker clients provide them with their cannabis and preferred product parameters, including product specs and with that information Growpacker turns it into a finished ingestible and edible product. Because let’s face it, if your still invested in cannabis stocks that don’t produce eatables, start smoking your profits away because you missed the boat.
On top of converting your THC and CBD into anything infused, Growpacker will take care of formulations, lab testing, packaging and; even the total distribution and transportation of your product. They have a turn key formula with all the required licenses to boot! And to make this even more delicious, the competitors are far behind. Growpacker was one of the first to begin this process and therefore have acquired all, I mean all, the necessary licenses to make this a growers dream come true. Currently Growpacker has +450 clients in the pipeline and nearly 100 that have started the on-boarding process for production with upwards of 10 inquires per day. If only all start-ups could be so fortunate…
Another satisfying point about Growpacker is that they do what they say. By the end of 2018 they said that they would have all their licences and they did. They also said that they are working on a high-profile brand relationship with THC infused beer start-up, Ceria Beverages Company, and it was solidified.
Speaking of Ceria, let’s look at the advisory board and shareholders of Growpacker. Keith Villa, the original founding member of Blue Moon Brewery, America’s #1 craft beer with annual revenue exceeding $250M and brand value of over $1B now owned and operated by MillerCoors, is a special advisor and shareholder to the company. He is also the one spearheading Ceria.
Furthermore, the special advisory board is made up of InterContinental Beverage Capital; (IBC) founders Joe Messina, Stephen F. Horgan and Doug Christoph who have all held top executive positions at Coca Cola and MillerCoors. (IBC) is involved in serving financial and operational planning, debt restructuring, investment, re-branding, business performance, revenue growth and profitability. These three powerhouses make it clear that Growpacker is starting on a solid business foundation.
And if this weren’t enough, Jon Cooper founding member of Ebbu Inc. a U.S hemp research company recently acquired by Canopy Growth Corporation for $429M USD is also a special advisor and shareholder. He brings everything research and development on the hemp platform to push the boundaries of cannabis tech.
Now if this is not a formula for success, I don’t know what is. Combining the turn key production and distribution formula with some of the most successful people in business along with a company who is far ahead of its competition, feels as comfortable a stock pick as a good old THC infused Ceria beer! Watch out Amazon, here comes Growpacker.
About Growpacker
Growpacker is a fully-licensed cannabis co-packing and bottling company that operates in California, now the worlds fifth largest economy and Americas largest consumer market. Taking a bifurcated approach on the industry, Growpacker will have the ability to manufacture products for both the regulated cannabis market (dispensaries) as well as the open market for products that are CBD only (grocery, convenience store, etc). They have proprietary THC & CBD infusion technologies, allowing them to design and manufacture the most premium cannabis-infused products on the market, including both water and oil-based products.
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency, representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid-cap Canadian-listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies, through online and offline channels.
Disclaimer:
All editorial content contained herein is solely the responsibility of Momentum PR and does not reflect, in any way, the opinions of Growpacker
—
Isabelle Arsenault
Media Relations
MomentumPR
p:+1.450.332.6939 m: +1.514.816.2611
w:www.momentumpr.com e: isabelle@momentumpr.com
- Published in Blog, Cannabis, growpacker, Marijuana, News Home, Technology
Canadian and US Cannabis Edibles and Consumer Products Market Set to Explode to US$ 4.1 Billion by 2022
Canopy Growth CEO Bruce Linton: “…related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol, sleep aids, appetite aids, sports drinks, medicines and pet care.”
If you can read them, the signs are there.
The marijuana edibles industry, that part of the recreational marijuana that be ingested as a candy, a chocolate, a candy bar or in a mixed drink or a beer is going to be huge and may very well eclipse that old standby the smokeable flower or bud.
During the summer ResearchAndMarkets predicted that the global cannabis infused edible products market would grow at an expected CAGR of 25.01% from 2018 to 2022. The infused beverage market would include CBD based
recovery drinks and tonics as well as potent THC infused beers.
An October 11, press release announcing a new report, “The Tasty Future of Cannabis Edibles,” by BDS Analytics and Arcview Research predicted that by 2022 the edibles market would exceed US$4.1 billion, up from US$1.5 billion, for the Canadian and US market in 2018.
A June article in Forbes ran the headline “New Data Shows that Smoking Marijuana is a Dying Trend.” The data it references is the 2018 Deloitte report on the emerging Canadian marijuana market and the Forbes story says, A recent analysis from Deloitte shows that “smokable marijuana” in the northern nation will generate in upwards of $5 billion in 2019. But the edibles sector is predicted to hit somewhere between $12 and $22 billion by the time the market is in full swing.”
According to the BDS and Arcview report the THC infused candy and chocolate market segment took the lion’s share of the US market at 60%. The press release quotes Troy Dayton the CEO of ArcView Market Research: “Established big brand food and beverage companies are beginning to take notice of the cannabis edibles market and this is likely just the tip of the iceberg.”
If anyone doubts that edibles and beverages are the next big thing they should remember Constellation Brands $4 billion investment in Canopy Growth. Of course if that doesn’t convince you then there is also the partnering dance between Coca-Cola and Aurora that somehow didn’t get off the ground. Just how big the market is going to be is still up for grabs.
In a video on TheStreet.com, Canopy Growth CEO Bruce Linton claimed that related cannabis products have the potential to disrupt as much as $500 billion annually in non-smokable areas and industries: alcohol sleep aids appetite aids sports drinks and medicines and pet care.
If you think the $500 billion figure was a bit too high Constellation Brands COO Bill Newlands predicted that the legal cannabis product market would hit $200 billion plus. “Our View is that in the next ten plus years, this is going to be a $200 billion business worldwide. And some would argue that’s understating the case.”
It’s not difficult to see why the edibles market segment is going to take off.
Smoking is, after all, bad for you. The more difficult question to answer maybe how to profit from what will be a long term market build out and development, one that, ResearchAndMarkets.com has predicted will grow at an astonishing rate of 25.91% CAGR for the years 2018-2022. At the moment almost every major Canadian marijuana company has either a beverage in development or edibles underway in a test kitchen. Edibles and beverages are made from oils and compounds removed from the plants by volatile or non-volatile extraction methods. One way of investing in this developing market lies in investing in those companies that are extracting THC and CBDs from marijuana and then selling it business to business for use in either medical marijuana or as food grade marijuana.
North Bud Farms (CSE: NBUD) is building out its 95 acre site in Low Quebec where it is in within 10 km of a major hydro power plant. Construction is scheduled to be finished Q1 2019 and at the moment is on time and within budget.
The company is also in the process of applying of for a production license under the Access to Cannabis for Medical Purposes Regulation (ACMPR). North Bud has cleverly tagged itself as Marijuana 2.0, in reference to the second wave of legal marijuana slated for October 2019, when the edibles and infused beverage market will be open for business. The company’s strategy is to supply two underserved markets by producing and selling certified pharmaceutical grade cannabis and GMP standard raw cannabis for the food and beverage industry. The company also intends to develop and market new products.
To that end it has recently signed a number of agreements that will help turn its words into action. On September 27, 2018 the company announced that it had signed an agreement with American firm Made By Science to license its cannabinoid infusion technology for food and beverage platform.
On October 17, 2018 North Bud announced that it had created a distribution company, “1017,” so named to commemorate the date of marijuana legalization Canada, and signed a letter of intent to acquire Janey’s, one of the six licensed marijuana accessory distributers in Ontario. Janey’s is also engaged in marijuana product development. North Bud intends to develop multiple products over a variety of product segments under the 1017 brand.
As of November 15, 2018 North Bud Farms, (CSE: NBUD) was trading at $0.25.
Given the predicted explosion in the marijuana consumables and edibles market laying a bet or two on companies in that field makes sense and one such company that bears keeping an eye on is Arev Brands International (CSE: AREV), formally Arev Nutrition Sciences. Arev originally saw life as a developer and marketer of coconut oil based health products. It is focussed on two distinct market sectors, consumer products and manufacturing as an ingredients supplier. Along the way the company also developed a unique extraction technology and this is where they fit into the consumables market segment.
In a press release on Bloomberg the company announced that it had reached a major milestone in extraction development with its partner Alternative Extracts Inc. Using its proprietary extraction system Arev has developed a
system that preserves flavour and aroma and which in the case of beverages may lengthen shelf life. It intends to manufacture finished oil products with proprietary strains bred to specifically address key health issues: anxiety, pain management, central nervous system disorders, insomnia and libido.
Arev also has an exclusive distribution agreement with the award winning full line of BARE Topical products.
In September 2018 the company completed its acquisition of BC Bud Depot. BCBD has one of the world’s largest cannabis seed banks. Over the last 14 years BCBD has won over 40 awards and was the first Canadian company to win an international award with “BC God Bud,” now Canada’s most award winning strain of all time.
On November 15, 2018 AREV was trading at $0.365.
This blog should not be construed as investment advice. Every investor is obligated to perform his or her own due diligence. In the interests of transparency Arev and North Bud Farms are both Momentum Public Relations clients.
- Published in AREV Nutrition Sciences, Blog, Marijuana, Medical Marijuana, NorthBud
TD Forecasts Marijuana Will Hike GDP by $8 Billion
The Chinese Are Coming
Synthetic CBDs and THC: Better Living Through Chemistry
TD Forecasts Marijuana Will Hike GDP by $8 Billion
Momentum Public Relations
Blog: September 26 2018
Just when you thought the Canadian marijuana industry was a slam dunk for becoming a dominant global force the Chinese are beginning to set up and take notice. According to a September story in The GrowthOp, the Postmedia marijuana industry news website, here come the Chinese.
Arcview Market Research and BDS Analytics have predicted that by 2027 the global marijuana market will be worth $US57 billion and you can be sure that Chinese business will see that as an attractive market. The Chinese will have to play catch-up, but catch-up is a game the Chinese play very well. Things will kick off when CannaTech: Hong Kong’s first cannabis investor symposium takes place on November 1st.
While Chinese investors will probably start to pour into the Canadian cannabis industry, they will as legislation changes, consider starting their own industry. Chinese herbal medicine has longed used marijuana as an ingredient.
URI Capital Management, one of the symposium sponsors was quoted in the story as saying: “Asia, more specifically China, is poised to leverage its unique advantages in Hemp and agriculture to become a dominant global leader. URI is proud to become the first Chinese financial conglomerate to focus on the Asian cannabis industry and will leverage the firm’s world-class research and investment resources to lead the way.”
If there is any doubt about the marijuana market drying up Canopy Growth (TSX:WEED) spun off its investment arm last Thursday and by Friday, Canopy Rivers Corp. (TSXV:RIV) market evaluation had more than doubled, according to a story in the Financial Post, to $1.6 billion. Before its IPO Canopy Rivers was valued at $600 million.
RIV has already made ten investments in Canada and one in Italy. According to the company website the investments include licensed producers, pharmaceutical formulators and retail.
As noted by Bloomberg it was the first time a bank, CIBC, had helped a marijuana company list on a Canadian stock exchange. CIBC led the deal with GMP Securities and Eight Capital.
The Bloomberg story contained the following quote: “We’re really trying to make this smart money that goes global,” Bruce Linton, chief executive officer of Canopy Growth and acting CEO of Canopy Rivers, said, “The scouting has been pretty active.”
Tilray (NASDAQ:TLRY) showed just how volatile marijuana stocks could be by rising 98% before plunging and then climbing back up to gain 44% on September 19, 2018. Tilray stock started climbing when the US FDA granted it permission to export medical marijuana for a trial in California as a treatment for essential tremors. The stock then came down to earth when a Florida Republican came down on the deal and said that the trial should be using American produced medical marijuana.
According to Bloomberg, Tilray shares rose to US$176 a share and then dropped like a stone to US$123 a share, finally ending the week up by 12%. Since it IPO in July, Tilray has risen by 800%.
Just as Aphria sold its interest in Liberty Health Sciences last week Aurora Cannabis (TSX:ACB) has spun off its American interests by spinning off Australis Capital (CSE:AUSA). Last Fall The TMX Group ruled that American federal overruled American state law and that consequently Canadian marijuana companies with American operations faced delisting if they did not exit the American market.
Like Canopy Rivers, Australis is an investment vehicle designed to aid American marijuana companies that have problems accessing capital and expertise. In an oversubscribed non-brokered pre-IPO private placement financing Australis raised $17 million at $0.20 a share. On Friday September 21st, Australis opened at $3.90 before closing at $3.16.
The next story should be filed under the 60s rubric of Better Living Through Chemistry. Cronos Group (TSX:CRON), one of the top Canadian vertically integrated marijuana producers, has announced a partnership with Boston-based Ginkgo Bioworks, a biotech startup. Under the partnership Cronos will fund research designed to produce synthetic CBDs and THC. Cronos is targeting a production price point of a thousand dollars a kilogram. The process will involve using fermentation to produce the cannabinoids.
Ginkgo Bioworks has had success producing expensive ingredients, perfume and flavours using synthetic DNA. The end product could be used in a variety of ways: including medical therapies, vaporizer cartridges and edibles. Cronos will invest up to $22 million in Ginkgo to fund research and development and in return for milestones give Ginkgo up to 14.7 million shares. In exchange Cronos will have the right to use and commercialize the resulting intellectual property.
Cronos is not the only marijuana LP looking into the future. On September 19th The Gazette reported that LP Organigram’s parent company, Organigram Holdings (TSXV:OGI), has invested $10 million in and formed an alliance with Hyasynth Biologicals, to develop synthetic phytocannabinoids, using the same techniques as Ginkgo, biofermentation. Hysaynth will be using its proprietary technique to produce the synthetic cannabinoids. As with Ginkgo, the process uses genetically engineered strains of yeast.
Finally, on September 19th the Financial Post reported that the Toronto-Dominion Bank had predicted that after legalization the marijuana industry will add up to $8 billion to the country’s real GDP. Canada’s measure of real gross domestic product will get a boost after the legalization of marijuana adds as much as $8 billion to the country’s economy, according to the bank. After legalization. Statistics Canada will face the daunting task of including both legal and illegal marijuana industry economic statistics in its forecasts.
Just how Statscan will assemble the black market statistics remains to be seen. Given that the illegal marijuana trade isn’t big on keeping records a lot of by guess and by golly will probably be used.
- Published in Blog
Coca-Cola Planning to Have Drinks With Aurora Cannabis?
Momentum Public Relations
Blog: September 18 2018
Coca-Cola Planning to Have Drinks With Aurora Cannabis
Global Soft Drink Market Pegged at US$605.6 Billion by 2025
Marijuana Industry Acquisitions Continue
Acquisitions, partnerships, branding and product development have all been on the increase in the legal marijuana industry this year as recreational marijuana legalization comes closer to becoming reality.
You can now begin to see a consumer product rollout that is remarkable in many ways. A new industry that cuts a broad swath in consumer goods is being developed and that Canadian industry is doing its best to reach out and conquer world markets. As well as medical and recreational marijuana CBD infused cosmetic and wellness products are being developed, as well as hemp clothing and THC infused beer.
On Monday September 17, 2018 the news broke that Coca-Cola (KO-NYSE) and Aurora Cannabis (ACB-TSX) were in talks about developing a non-psychoactive cannabis infused soft drink. CNBC reported that pot stocks jumped on the news with Aurora gaining more than 15% as of mid-day. Speculation exists that Coke wants to develop a CBD infused beverage in Canada so that it can launch it in America when marijuana laws there are relaxed.
Earlier in the summer Molson-Coors announced a deal with Hydropothecary (HEXO-TSX) to develop a THC infused beer. Marijuana is going mainstream faster than imagined and industry players are scrambling to gain a piece of what may be one of the last and biggest market rollouts.
Coca-Cola is the largest beverage company in the world and if the Molson-Coors (TAP-NYSE) Hydropothecary beer agreement didn’t give the industry legitimate credibility then the forthcoming agreement with Coca-Cola should. Based on information from an anonymous source the story said that if consummated the partnership would develop health-focused beverages or recovery drinks designed to alleviate inflammation, pain and cramping.
In a statement Aurora issued to CNBC the company described the infused-beverage space as having “incredible potential.” In a statement that Coca-Cola sent to CNBC Coke said: “Along with others in the beverage industry, we are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world. The space is evolving quickly. No decisions have been made at this time.” The anonymous source described the discussions as “serious.”
Grand View Research has predicted that the global soft drink market will hit US$605.6 billion by 2025.
Crop Infrastructure (CROP-CSE) announced on September 13, 2018 in a press release that it too was entering the soft drink market with a cannabis-infused beverage, Canna Drink, that would have zero calories, be non-GMO, ketogenic-friendly and be available in both tea and coffee versions. Crop Infrastucture Director and CEO Michael Yorke said in the release that: “We see it as a tremendous opportunity for Crop Infrastructure’s branding & IP portfolio and as an auxiliary opportunity for each of our cultivation tenants globally.”
“Functional beverages are a new class of products that offer beyond basic nutritional ingredients, including vitamins, minerals, herbs, amino acids and probiotics. We believe that cannabis’s medically known benefits will enhance our own formulations, so we are bang on target with our CANNA DRINK line.”
Crop Infrastructures is a sophisticated company that has modelled its business plan on REITs, creating a real estate type marijuana investment trust. It owns properties in jurisdictions where recreational marijuana is legal and offers tenants infrastructure, branding and expertise. The company has recently expanded to Jamaica . Crop has also announced that by the end of the year it will open two retail locations in Northern Italy to sell the Urban Juve product line of hemp oil infused wellness, cosmetic and therapeutic products.
While the secondary market, products infused with CBDs, is roaring into life, acquisitions and agreements are still being made as legalization approaches.
Aurora Cannabis’ $290-million all share deal to buy ICC Labs is the latest acquisition to fuel rising share prices. Aurora has already bought up to 10 companies in the last two years. The deal is a reminder that Canada is not the only marijuana playing field and that industry leaders are busily paving the way for international expansion when more countries legalize recreational consumption.
In a telephone interview with The GrowthOp, Postmedia’s marijuana news website, Aurora’s chief corporate officer Cam Battley said: “We feel a significant sense of urgency to rapidly establish a powerful global footprint. We see ICC as the jewel of the South American market. This is going to be our anchor in South America and we have very big plans for that continent.”
The jewel that prompted Aurora’s purchase was the fact that ICC has 70% or more of the Uruguayan market. Uruguay legalized marijuana in 2013, becoming the first country in the world to do so. As well as having majority market share in Uruguay, ICC Labs also comes with Columbian licenses to grow medical marijuana and an agreement to sell CBD products to Mexico.
In the meantime, Aphria (APH-TSX) has more or less cleared the decks by selling its interest in Liberty Health Sciences for almost $60 million. According to a Canadian Press article published on September 6, 2018 in the Financial Post Aphria has sold the shares to several investors and the deal contains an option to repurchase the shares within five years.
Aphria now has money in its war chest to finance further acquisitions and opportunities. TSX regulations forced the company to sell its shares in Liberty because marijuana is illegal under federal American legislation and Aurora was threatened with delisting if it did not comply. The company intends to return to the American market when regulations change, hence the buyback option.
Canada’s largest marijuana producer, Canopy Growth(WEED-TSX), appears to just keep getting bigger. On September 5, 2018 it announced that it had acquired Hiku Brands in exchange for Canopy Growth shares. The deal improves Canopy’s retail and branding position.
Hiku is an attractive acquisition for Canopy. It has a subsidiary, DOJA Cannabis, a licensed ACMPR producer with two British Colombia based production facilities in the Okanogan Valley. Another subsidiary, TS Brandco Holdings has one of four master retail licenses in Manitoba. The company also has a chain of retail outlets branded as Tokyo Smoke in British Columbia, Alberta and Ontario.
All of this only goes to show that the Canadian marijuana industry is a global leader and that as countries begin to decriminalize possession, Canadian companies will be able to significantly grow their operations because of their existing footprint. All the major Canadian marijuana producers have foreign operations.
This blog was written for information purposes only and should not be mistaken for investment advice. In the interests of transparency Crop Infrastructure is a Momentum client.
Genacol Canada Corporation and Tetra Bio-Pharma Team Up to bring Innovative Cannabinoid Treatments to Self-Care Market in Canada
Momentum Public Relations
Press Release: August 14 2018
Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB: TBPMF), is pleased to announce that they have concluded a Development and Commercialization agreement with Genacol Canada Corporation. Tetra Bio-Pharma will develop a cannabinoid derived oral capsule and a topical cream for treating joint pain and inflammation. Genacol will be responsible for the promotion and sales of these products throughout their network in Canada. According to industry statistics the market for topical pain relief products exceeded $2.5 billion. The companies plan to launch the products in 2019.
|
Tetra Bio-Pharma will use its formulation and regulatory expertise and clinical trial data from its topical cannabinoid and encapsulated cannabis oil (PPP005) trials to create innovative products for Genacol. Tetra Bio-Pharma will work with regulatory to bring these products to markets within Genacol’s sales network. “We are thrilled to partner with Genacol, a market leader in Canada with a sales network in over 40 countries, these products will command a great deal of exposure,” says Dr. Guy Chamberland, interim CEO and Chief Scientific Officer of Tetra Bio-Pharma. “Tetra is in the business of developing cannabinoid derived prescription and natural health products and this agreement will enable Tetra Bio-Pharma to expand the number of offerings to our patients.”
“We are extremely excited about the potential of this partnership we have created with Tetra Bio-Pharma, a world leader in developing cannabinoid derived prescription and natural health products,” stated Martin Vidal, President & Chief Executive Office for Genacol Corporation. “Our research team at Genacol are great believers in the therapeutic properties of cannabinoids. These products that Tetra Bio-Pharma is developing and Genacol will promote and commercialize are expected to play an important role in the pain and inflammation market in Canada. We estimate that these products will generate several millions of dollars in sales for Genacol in Canada.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
About Genacol Corporation
Genacol Corporation Canada is a leader in the development and marketing of natural health products primarily related to the treatment of joint pain and the maintenance of joint health. Its mission is to improve the quality of life of its customers by offering them a range of innovative natural products. Building on its success in Canada, Genacol has also developed in recent years an international presence with Genacol brand products available in more than 40 countries, including Latin America, Europe, Asia, the Middle East, Africa and the United States. In addition, the Genacol trademark is registered in 81 countries worldwide. The success of Genacol is based on its collagen manufactured using a proprietary process called “AminoLock® Sequential Technology”, which is an ingredient in many of Genacol’s products.
For more information visit: www.genacol.ca/en/about-us/
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-817-2514
Investors@tetrabiopharma.com
Media Contact:
ACJ Communication
Daniel Granger
Danel.granger@acjcommunication.com
514-840-7990
514-232-1556
Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/b867bc64-b347-4043-80ff-c7d022ab7eff
http://www.globenewswire.com/NewsRoom/AttachmentNg/3464aadf-745d-4d04-b230-b71f0c82188a
- Published in Tetra Bio Pharma
Tetra Natural Health Announces Upcoming Launch of Hemp Energy Drink
Momentum Public Relations
Press Release: July 19 2018
Tetra Natural Health Inc., a division of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP) (OTCQB:TBPMF), announced that it will be commercializing Hemp Energy Drink, a caffeinated energy drink containing hemp, that received a Temporary Marketing Authorization (TMA) by Health Canada. Tetra intends on launching this product ahead of the upcoming legalization as it begins to position itself as a player in the natural health product market.
Hemp Energy Drink is developed for those who want to have a clear and focused mind and live an active and fun lifestyle. It can be consumed whenever people are in need of energy whilst working, driving or playing sports and leisure activities. The functional benefits of hemp energy drink are mainly to help for concentration, alertness and to contribute to mental performance and reduction of fatigue.
Hemp Energy Drinks are already available in the U.S.A. and in several European countries, and the European Food Safety Authority confirmed the positive health effects related to the ingredients of Hemp Energy Drink.
Tetra Natural Health has a team of natural health experts that have been preparing to commercialize products containing hemp or that act on the cannabinoid receptors under the existing Food and Drug regulations. To lead and support the team, Tetra recently announced the arrival of Richard Giguere, Executive Vice President Commercial Operations who will implement and oversee the natural health product commercial sales and growth strategy.
Richard has more than 20 years’ experience in sales and marketing including OTC, natural products and original pharmaceutical medications. His arrival was perfectly aligned with Tetra Natural Health’s goal to develop and sell hemp, cannabis and cannabinoid-based OTC (self-care) products to leverage the post-legalization market. Tetra obtained the rights to the TMA and plans on expanding this food product line as part of a structured sales driven growth plan.
About Tetra Natural Health:
Tetra Natural Health Inc. is a subsidiary of Tetra Bio-Pharma Inc, (TSX-V: TBP) (OTCQB: TBPMF) that is focusing on retail commercialization of hemp, cannabis or cannabinoid-based products authorized by Health Canada for sale.
Tetra Bio-Pharma is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of its mission, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Natural Health Inc.:
Richard Giguere, Executive Vice President, Commercial Operations
richard.giguere@tetrabiopharma.com
438 899-7575 ext 210
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990
M: 1 514 232 1556
- Published in Tetra Bio Pharma